Conversely, neither the BV change peak in PTPRD nor the T2LV change peak in NEDD4L were associated with MS risk3, and no putative BV change or T2LV change peaks (p < 1 × 10–6) colocalized with MS risk. Here, PTPRD is linked to myeloid sarcoma.